The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Peking University

Status: Enrolling

Conditions: Peripheral T Cell Lymphoma

Treatments: Drug: Transplant, Autologous

Study type: Observational

Funder types: Other

Identifiers

NCT04489264

ASCT for PTCL

Details and patient eligibility

About

The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 & PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with confirmed pathological diagnosis of aggressive PTCL
• Age 18-65 years old
• Achieving CR or PR after first-line therapy

Exclusion criteria

• Subtypes with a more indolent course, including precursor T/natural killer neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, Sézary syndrome, and primary cutaneous CD30-positive disorders.

Trial design

60 participants in 2 patient groups

ASCT group

Description:

patients who achieved CR or PR after 6-8 cycles first-line therapy receive ASCT as consolidation therapy

Treatment:

Drug: Transplant, Autologous

Observation group

Description:

patients who achieved CR or PR after 6-8 cycles first-line therapy finish their therapy and go into follow-up